Arformoterol Tartrate

酒石酸阿福特罗

Report date: 2025/10/27 20:00:53
NME

Base Information

Drug NameArformoterol Tartrate
Drug Alias Name阿福莫特罗arformoterolum(R,R)-formoterol酒石酸福莫特罗(R,R)-eformoterol +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptor
Therapy Area/IndicationsBronchoconstrictionEmphysemaPulmonary Disease, Chronic Obstructive +[5] 
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/10/06
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSumitomo Dainippon
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Hechen Pharmaceutical Co LtdHainan Star Pharmaceutical Co LtdJinyao Yongguang (Hebei) Pharmaceutical Co Ltd
Inactive CompaniesSumitomo Pharma America IncLupin LtdHunan Warrant Pharmaceutical Co Ltd
Active IndicationsBronchoconstrictionPulmonary Disease, Chronic Obstructive
Inactive IndicationsEmphysemaBronchitis, ChronicBronchitis

Other Information

ATC CodeR03
Related LinksWikipediaDrugBankKEGG